New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting

by Cannita, Katia, Paradisi, Stefania, Cocciolone, Valentina, Bafile, Alberto, Rinaldi, Lucia, Irelli, Azzurra, Lanfiuti Baldi, Paola, Zugaro, Luigi, Manetta, Rosa, Alesse, Edoardo, Ricevuto, Enrico, Ficorella, Corrado
Published in Cancer Med (2016)

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis

by Cocciolone, Valentina, Cannita, Katia, Calandrella, Maria Letizia, Ricevuto, Enrico, Baldi, Paola Lanfiuti, Sidoni, Tina, Irelli, Azzurra, Paradisi, Stefania, Pizzorno, Laura, Resta, Valter, Bafile, Alberto, Alesse, Edoardo, Tessitore, Alessandra, Ficorella, Corrado
Published in Oncotarget (2017)

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations

by Cocciolone, Valentina, Cannita, Katia, Tessitore, Alessandra, Mastroiaco, Valentina, Rinaldi, Lucia, Paradisi, Stefania, Irelli, Azzurra, Baldi, Paola Lanfiuti, Sidoni, Tina, Ricevuto, Enrico, Dal Mas, Antonella, Calvisi, Giuseppe, Coletti, Gino, Ciccozzi, Antonietta, Pizzorno, Laura, Resta, Valter, Bafile, Alberto, Alesse, Edoardo, Ficorella, Corrado
Published in Oncotarget (2018)